Curia to bolster local commercial manufacturing capabilities

Curia, formerly known as Albany Molecular Research Inc. (AMRI), a contract development and manufacturing organization (CDMO), will be expanding its commercial manufacturing capacity at its Rensselaer, NY, facility. The increased capability to flexibly manufacture active pharmaceutical ingredients (APIs) will help strengthen Curia’s ability to partner with customers, as the CDMO will be able to accommodate small-scale to large-volume requirements with delivery, the company says. The Rensselaer center has been providing APIs to pharma companies for over 100 years.

The expansion is anticipated to be finished within 18 months, adding to Curia’s current API manufacturing facilities in the US, France, Spain, Italy and India.

The company is investing more than $35 million in these expanded manufacturing and product-handling solutions for complex small molecules. The expansion will feature new vessel capacities that are expected to more than double the site’s batch-size scaling and product output.

Curia also offers fill-finish services, and had been chosen to support the development and manufacture of lipid excipients for the Pfizer-BioNTech Covid-19 vaccine.